-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On July 25, 2021, Innovent Biologics announced that in patients with advanced malignant tumors, its phase 1a clinical trial of the anti-PD-1/TIGIT bispecific antibody IBI321 has completed the first patient administration
IBI321 is a PD-1/TIGIT bispecific antibody jointly developed by Cinda Biologicals and Eli Lilly and Company, and is developed in China by Cinda Biologicals
The results of various preclinical studies have shown that IBI321 retains the pharmacodynamic activity of PD-1 inhibitors, and at the same time inhibits the signal of TIGIT, and synergistically enhances the efficacy
Note: The original text has been deleted
Reference materials:
[1] Innovent Announces the First Patient Dosed in the Phase 1 Study of IBI321 (Anti-PD-1/TIGIT Bispecific Antibody) in Patients with Advanced Malignant Tumors.